A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder

Trial Profile

A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2018

At a glance

  • Drugs ABX 1431 (Primary)
  • Indications Gilles de la Tourette's syndrome; Tic disorders
  • Focus Therapeutic Use
  • Sponsors Abide Therapeutics
  • Most Recent Events

    • 10 Apr 2018 According to an Abide Therapeutics media release, data from this trial will be presented at the American Academy of Neurology (AAN) 70th Annual Meeting 2018.
    • 02 Nov 2017 Status changed from recruiting to completed.
    • 18 Apr 2017 According to an Abide Therapeutics media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top